Source comparison
Hexarelin for Fat Loss: Growth Hormone Secretagogue Comparison
Understanding how hexarelin for fat loss compares to other peptides in the GH secretagogue class is essential for selecting the appropriate compound for specific research or clinical applications. The table below contrasts hexarelin with Ipamorelin, GHRP-2, an
This comparison does not assign a generated winner or score.
- Understanding how hexarelin for fat loss compares to other peptides in the GH secretagogue class is essential for selecting the appropriate compound for specific research or clinical applications. The table below contrasts hexarelin with Ipamorelin, GHRP-2, and GHRP-6 across key pharmacological parameters.
- Hexarelin
- 15–25 ng/mL
- Moderate (20–30% increase)
- High (30–50% increase)
- Rapid (8–12 weeks)
- Short-term maximal GH output; aggressive fat loss phases
- Highest potency but side effect burden limits long-term use. Cycle on/off or reserve for 4–6 week protocols
- Ipamorelin
- 8–15 ng/mL
- Minimal (<5% increase)
- Minimal (<10% increase)
- Slow (16+ weeks)
- Long-term body recomposition; maintenance protocols
- Most selective profile. Ideal for extended use with minimal HPA disruption
- GHRP-2
- 10–18 ng/mL
- Moderate (15–25% increase)
- Moderate (20–35% increase)
- Moderate (12–16 weeks)
- Balanced potency and tolerability; moderate-term fat loss
- Middle ground between hexarelin's power and ipamorelin's selectivity
- GHRP-6
- 9–16 ng/mL
- Low (10–15% increase)
- Low (15–20% increase)
- Appetite stimulation contexts; joint/connective tissue support
- Notable ghrelin-mimetic hunger increase. Less suitable for deficit-driven fat loss
- The bottom line: hexarelin for fat loss delivers the highest GH amplitude, making it the most effective secretagogue for rapid adipose reduction in time-sensitive contexts. However, prolactin elevation and faster receptor desensitization mean it is best reserved for short, aggressive phases rather than sustained year-round use. For long-term metabolic management, Ipamorelin offers superior tolerability and sustained efficacy without HPA axis disruption.